Company Filing History:
Years Active: 2025
Title: Innovations of Xinmin Zhang in Antibody Development
Introduction
Xinmin Zhang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His innovative work has led to the creation of a unique single-domain antibody that targets human CD47.
Latest Patents
Xinmin Zhang holds 1 patent for his invention titled "Human CD47-targeting single-domain antibody and use thereof." This patent relates to an anti-CD47 single-domain antibody and its applications, as well as a method for preparing the antibody. The single-domain antibody comprises a complementarity-determining region (CDR) selected from specific sequences, which enhances its effectiveness in targeting CD47.
Career Highlights
Xinmin Zhang is currently associated with Shanghai Escugen Biotechnology Co., Ltd. His work at this company focuses on advancing biotechnological solutions that can have a profound impact on medical treatments. His expertise in antibody development has positioned him as a key figure in the industry.
Collaborations
Xinmin Zhang collaborates with talented professionals in his field, including Xiangyu He and Weihong Nian. These collaborations foster innovation and contribute to the advancement of biotechnological research.
Conclusion
Xinmin Zhang's contributions to the field of biotechnology, particularly through his patented innovations, highlight his role as a leading inventor. His work continues to pave the way for advancements in medical treatments and antibody development.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.